Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib + Pembrolizumab in NSCLC and HR+ HER2- Breast Cancer
NCT02779751Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of abemaciclib in non-small cell lung cancer (NSCLC) and breast cancer (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Serious Adverse Events at 6 months and Non-Serious Adverse Events at 6 months. Started Nov 2016; status: active, not recruiting.
02
Drugs
abemaciclib
03
Conditions
non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT02779751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02779751.